These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9273360)

  • 21. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A; Ward RJ; Peters TJ; Crichton RR
    Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
    Xu X; Sutak R; Richardson DR
    Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
    Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.
    Wallace KB; Sardão VA; Oliveira PJ
    Circ Res; 2020 Mar; 126(7):926-941. PubMed ID: 32213135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
    Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
    J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
    Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity.
    Kwok JC; Richardson DR
    Mol Pharmacol; 2002 Oct; 62(4):888-900. PubMed ID: 12237336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio.
    Childs AC; Phaneuf SL; Dirks AJ; Phillips T; Leeuwenburgh C
    Cancer Res; 2002 Aug; 62(16):4592-8. PubMed ID: 12183413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
    Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes.
    Santostasi G; Kutty RK; Krishna G
    Toxicol Appl Pharmacol; 1991 Mar; 108(1):140-9. PubMed ID: 2006501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
    J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
    Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
    Chenoufi N; Hubert N; Loréal O; Morel I; Pasdeloup N; Cillard J; Brissot P; Lescoat G
    J Hepatol; 1995 Aug; 23(2):166-73. PubMed ID: 7499788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.
    Glickstein H; El RB; Link G; Breuer W; Konijn AM; Hershko C; Nick H; Cabantchik ZI
    Blood; 2006 Nov; 108(9):3195-203. PubMed ID: 16835377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
    Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron transport and subcellular distribution in Hep G2 hepatocarcinoma cells.
    Parkes JG; Templeton DM
    Ann Clin Lab Sci; 1994; 24(6):509-20. PubMed ID: 7847779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.